Two additional immunohistochemical studies of 74 [11] or 137 [12] CCRCCs revealed heterogeneous data and conclude that the survival rate is less-favorable in the CCRCC group with high galectin-3 expression. The gene discussed is LGALS3; the disease is nonpapillary renal cell carcinoma.